Navigation Links
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
Date:4/15/2008

t of MS. That is why these results are encouraging -- because we are seeing substantial benefits of FTY720 maintained over time in this clinical trial."

FTY720 is a novel, once-daily, oral treatment in worldwide Phase III clinical development for the treatment of relapsing-remitting MS, the form of the disease that affects approximately 85% of people diagnosed with MS.

More than 2.5 million people worldwide are affected by MS, the most common non-traumatic cause of neurological disability in young people. Regulatory filings for FTY720 are expected in the US and EU before the end of 2009.

"The FTY720 Phase III program is the largest conducted in MS to date, and demonstrates our long-term commitment to the field of MS therapy," said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. "It is especially encouraging to see that FTY720 continues to demonstrate sustained efficacy by helping the majority of patients to remain free of relapses as the study progresses."

FTY720 has the potential to be the first in a new class of therapies for MS that act on inflammation by modulating sphingosine-1-phosphate receptors (S1P-R), reducing the number of inflammatory immune cells, called lymphocytes, from reaching the brain. In addition, FTY720 reaches the brain and S1P-Rs are present on central nervous system (CNS) tissue, so FTY720 may have a direct beneficial effect on MS within the CNS. This additional potential mechanism of action is supported by new preclinical data being presented at AAN.

The Phase II study presented at AAN began with a six-month placebo-controlled phase in which 281 patients with relapsing MS received placebo, FTY720 1.25 mg or FTY720 5 mg once-daily. This was followed by a long-term extension in which all patients took FTY720. At the end of three years, 173 patients were in the extension, which is still ongoing. The study has been conducted in Canada and 10 European countries.

Results from
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
2. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
6. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
9. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
10. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
11. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... today, which integrates with HealthKit in iOS 8 and ... with their doctors. The app harnesses native iOS technologies ... patients to maintain a robust connection with their doctors ... wearable health devices and the data they collect is ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... growth stage. Both established medical-device providers as well as ... Eastern European region, while simultaneously looking at ways to ... this sector. Using distributors is one of the effective ... the medical devices distribution market in Eastern European and ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
(Date:9/30/2014)... September 30, 2014 Two revolutionary procedures now ... treatment of gum disease a far less painful and ... , “If you’ve ever felt electric shock waves surge through ... a cold beverage, it’s possible you already know the impact ... is a general dentist in West Palm Beach, and a ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
(Date:9/30/2014)... has made progress in reducing the stigma associated with ... post-traumatic stress disorder, but more improvement is still needed, ... efforts of both the Defense Department and the Veterans ... members still do not seek needed care for ... effort to promote treatment as a way to reduce ...
(Date:9/30/2014)... ANN ARBORThe discovery of a gene mutation that causes ... development of drugs that block the rapid, unstoppable cell ... at the University of Michigan and the U-M Health ... devastating disease dyskeratosis congenita, in which precious hematopoietic stem ... DC age prematurely and are prone to cancer and ...
(Date:9/30/2014)... 30, 2014 FDA-approved injectable dermal ... acid) are used in several procedures that are ... patients, but are primarily used for wrinkle treatment ... particular, these fillers are being used as popular ... smoother skin in the hands. (1) (2) Dr. ...
Breaking Medicine News(10 mins):Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 3Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 4
... sexual adaptation shows that evidence is building for what ... appearing in Current Directions in Psychological Science, physical and ... males have evolved to deliver their sperm more effectively ... people are familiar with the idea of animals competing ...
... spider, a cousin to the well-known black widow, is increasingly ... is belongs to a group that is officially known as ... as "fiddleback" spiders or "violin" spiders because of the violin-shaped ... and thorax). ,The spiders are generally found in ...
... Union Minister of State for Environment and Forests, Shri ... century just as information technology dominated the last century. ... Consultative Committee of the Ministry of Environment and Forests, ... on Genetic Engineering Approval Committee has been vacated today ...
... In line with Ranbaxy Laboratories aggressive international expansion ... has solidified the acquisition of Be-Tabs Pharmaceuticals ... ,The deal is valued at R500 million ... fifth largest generic pharmaceutical company in South Africa. ...
... the champagne bottles which contained the weed killer that poisoned ... to him by a person well known to him-bowling coach Mustaq ... the team manager Talat Ali was witness to this. ... and Talat Ali knew the person or persons who handed over ...
... Concern over side effects of various drugs could be ... profile recalls like Vioxx, the osteoarthritis drug. ... Boston researchers at the Tufts-New England Medical Center. ... of Health Affairs, researchers compared half a dozen risky ...
Cached Medicine News:Health News:Louisiana Residents Warned Against Brown Recluse Spiders 2Health News:Biotechnology Will Dominate The 21st Century 2Health News:Ranbaxy Labs Extends Roots in South Africa 2Health News:Ranbaxy Labs Extends Roots in South Africa 3Health News:Drug Risks Must Be Balanced Against Benefits, Researchers 2
... single use loading unit (SULU), the EEA™ ... staples., ,Immediately after staple formation, a ... excess tissue, thus creating a circular anastomosis. ... handles firmly as far as they will ...
... The Scantibodies Calcitonin Immunoassay is a ... of calcitonin. Two different goat polyclonal antibodies ... affinity chromatography to be specific for well-defined ... the quantitative determination of Calcitonin in human ...
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Calcitonin RIA Kit...
Medicine Products: